The Impact
of Thyroid Eye
Disease (TED)

An educational TED Augmented
Reality experience

GBR-632-26-80009 | Feb 26

Medical Disclaimer
& Privacy Policy

Important information — please read

This webAR experience is provided for educational and awareness purposes only.

It uses on-device face tracking and visual effects to simulate the appearance of certain signs that may be associated with Thyroid Eye Disease (TED).

This experience is not a medical device, not a diagnostic tool, and not intended to predict, prevent, monitor, treat, or cure any disease.

The visual effects are illustrative only and may not reflect how TED appears for any individual, including severity, progression, or combinations of symptoms.

This experience does not provide medical advice. If you have symptoms or concerns, please consult a qualified healthcare professional.

This tool is not intended to represent how TED manifests in all patients and users should be aware that the signs, symptoms and how each patient experiences TED may vary. All image representations have been created and tested with healthcare professionals experienced in the diagnosis and management of TED and deemed to be suitable to depict some of the changes that can be seen with the disease.

Safety and suitability

Do not use if you are sensitive to visual effects, experience dizziness, nausea, or discomfort. Stop immediately if you feel unwell.

Use in a safe environment and remain aware of your surroundings.

Privacy

Face tracking is processed on your device to apply effects. This experience does not store or retain face images.

No responses to questions within this experience will be captured, stored, or retained. No images will be stored or collected during this experience.

By selecting “I Agree”, you confirm that you have read and understood the information above and wish to proceed.

The impact of TED from
a patient’s perspective

Before you begin

Please click to watch this 1 minute video of a patient discussing her experience with TED before continuing. Allow access to device camera when asked.

Processing...

Whilst your image is being processed, did you know…

71% of patients report that thyroid eye disease negatively impacts their self-confidence. ¹*

1) Terwee CB et al., Br J Ophthalmol. 1998;82:773–779

*

Based on n=50/70 patients with TED who responded to the Graves’ orbitopathy quality of life questionnaire (GO-QOL), who reported their self confidence had been influenced a little or seriously by their eye disease.

TEPEZZA®▼ (teprotumumab) is the first UK targeted treatment indicated in adults for the treatment of Moderate-To-Severe Thyroid Eye Disease (TED)¹

Efficacy of teprotumumab in adults with active
moderate-to-severe TED at week 24:

Proptosis response*

vs 10% (n=4/42) with placebo^2.3 Intention To Treat analysis. Treatment difference 73.45% [58.89 to 88.01]; P<0.001

Diplopia response**

vs 29% (n=8/28) with placebo³ Intention To Treat analysis. Treatment difference 39% [95% CI: 16 to 63]; P=0.001

Mean change in GO-QOL overall score***

vs 4.43±2.10 with placebo (n=42)³ Treatment difference 9.36 [95% CI: 4.08 to 14.64]; P<0.001

▼ This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.

* A proptosis responder was defined as having a ≥2-mm reduction in proptosis from baseline in the study eye without deterioration (≥2-mm increase in proptosis) in the non-study eye at week 24.

** A diplopia response was defined as a reduction in Gorman diplopia score of ≥1 grade from baseline.

*** A mixed-model repeated-measures analysis of covariance was used to assess the secondary outcome change from baseline in overall score on the Graves’ ophthalmopathy-specific quality-of-life (GO-QOL) questionnaire.

1) https://www.amgen.co.uk/media/news-release/2025/05/amgens-tepezza-teprotumumab-granted-marketing-authorisation-as-the-first-targeted-treatment-specifically-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted-in-the-United-Kingdom. Accessed Jan 2026

2) TEPEZZA®▼ (teprotumumab) SmPC. 3) Douglas RS, Kahaly GJ, Patel A et al N Eng J Med 2020; 382(4):341-352.